

Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox

Issue 2: 7 November 2024

Table of Contents

Epidemiology	01
Regulatory	02
Vaccines	02
Supply	02
Manufacturing capacity	02
Procurement	03
Donations	03
Delivery and uptake	04
Testing and therapeutics	05
Financing	06
In the News	07

Latest Mpox Response Insights

The highlights and latest updates sections below contain our latest analysis and most recent updates across all topic areas since the [last edition](#) of the report. The updates since the last edition are also highlighted in the body of the report.

New cases of mpox reported in the UK and other regions, while cases appear to stabilize in the Democratic Republic of Congo:

The United Kingdom reported the first case of clade 1b mpox, later identifying three additional cases that were household contacts of the index case. The index case acquired mpox while traveling in countries in Africa that are seeing community cases of mpox. The UK Health Security Agency is offering testing and vaccination to contacts as needed, and believes the risk of spread in the greater population is low at this time. The UK is the third high-income country to report mpox cases (Germany, Sweden), and the 6th country outside of Africa to report cases (Germany, Sweden, Pakistan, Thailand, India). Mauritius reported the first case of mpox (clade unspecified) on October 27th, and no further cases have been identified at this time. Uganda, which shares a border with the DRC, has seen mpox cases rising with a cumulative 359 cases across 35 districts and clade 1b mpox has been isolated from all sequenced cases. In the wake of vaccination campaigns rolling out in several provinces in the Democratic Republic of Congo, new cases appear to be slowing down. Laboratory confirmed cases have dropped from an average of 400 positive per week in July to between 200-300 positive per week in the recent weeks. It is estimated around 51,649 (1.29%) people have been vaccinated, with a goal of vaccinating 4 million people.

Latest updates at a glance:

- The WHO has granted Cepheid's Xpert Mpox and Roche's cobas MPXV emergency use listing. Xpert Mpox is the first near point-of-care diagnostic available.
- Contipharma's two rapid diagnostic tests, LAMPOX and Monkeypox Virus Antigen Rapid Test Kit, recently received market access authorization in the Democratic Republic of Congo. At this time, Africa CDC has emphasized no antigen rapid diagnostic test has demonstrated the minimum requirement for mpox testing.
- Nord Kivu, Sud Kivu, and Tshopo provinces in the Democratic Republic of Congo have achieved or surpassed vaccination targets with reported coverage of 142.8%, 121%, and 91.3% respectively. Kinshasa is the next priority province to launch vaccination.
- Rwanda has met 100% of the total vaccination target, and Nigeria plans to launch vaccinations on November 18th.
- Africa CDC has received \$1.3 billion in financial pledges against the original budget request of \$600 million laid out in the Continental Response plan.
- There have been no new vaccine donation pledges or vaccine deliveries in the last two weeks. More vaccines are expected to arrive on the continent in November. 975,000 vaccine doses will be allocated in November and delivered in December.
- The Africa CDC has launched an mpox [dashboard](#) that tracks the epidemiological situation, programmatic response, resources, and partnerships in the response.


Introduction

The COVID-19 pandemic exposed significant global inequities in the access to therapeutics, vaccines, testing, and other medical interventions that could limit the range and impact of the disease. These global inequities are not limited to the COVID-19 pandemic and need to be critically addressed in the ongoing mpox outbreak. Through our QuickStart newsletter updates, we aim to serve as an external, independent source for tracking actions to meet commitments, catalyzing additional commitments to meet the need, and holding the world to account for the mpox response.

Epidemiology

On August 13th, 2024, the Africa CDC declared the mpox outbreak a Public Health Emergency of Continental Security (PHECS), which is the first time this designation has been used since the agency's inception. On August 14th, 2024, the World Health Organization declared the mpox outbreak a public health emergency of international concern (PHEIC). Mpox is an infectious disease that [causes symptoms](#) such as a painful rash, fever, muscle aches, and headaches. Symptoms [can last](#) 2-4 weeks, and the virus can be passed to others until all sores have healed and a new layer of skin has formed. Mpox [spreads](#) through close skin to skin contact with someone who has mpox, through contact with contaminated objects or needle injuries, during pregnancy or birth, or from exposure to an animal with mpox. Currently, the animal reservoir of mpox is unknown.

MPXV clades detected in Africa
 from 1 Jan 2022, as of 13 Oct 2024



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its borders or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Date Source: World Health Organization
 Map Revision: WHO Health Emergencies Programme
 © WHO 2024. All rights reserved.

Source: WHO 2022-2024 Mpox Outbreak: Global Trends

There are [two clades](#) of the virus: clade I (subclades Ia and Ib) and clade II (subclades IIa and IIb). Clade I is more likely to cause severe illness and death, and is currently spreading in Central and Eastern Africa. Historically clade I mpox cases typically resulted from contact with an infected animal, but subclade Ib cases appears to be [spreading](#) mostly through human-to-human contact. Subclade Ib is a newer subclade and its spread from the Democratic Republic of Congo (DRC) to surrounding countries (Burundi, Kenya, Rwanda, Uganda) is partly what triggered the PHEIC declaration. Clade II was the cause of the 2022 outbreak and usually causes less severe illness, and is endemic to West Africa.

[In 2024 alone](#), through 7 November 2024, **there have been 50,840 suspected cases of mpox from 19 African Union member states**. Out of the suspected cases, 10,741 (21.13%) have been confirmed and 1,083 deaths (Case fatality rate: 2.13%) were reported. [In the last week](#), there were 1,020 suspected cases, 280 (27.45%) of those were confirmed, and there were 8 (Case fatality rate: 0.78%) deaths. Of all [confirmed](#) cases in 2024, 38% are in children though some countries are reporting higher burden among children such as Burundi (48.4%), Central African Republic (50%), and Liberia (67%). The disease has spread to all 5 regions of Africa. Mauritius recently [reported](#) the first case of mpox in the country. Cases in the Democratic Republic of Congo appear to be [stabilizing](#) with confirmed cases dropping from around 400 a week in July to around 200-300 a week. However, mpox cases in Uganda [have risen](#) to 359 cases across 35 districts. In Uganda, children account for only 12.5% of cases compared to nearly 50% in the DRC. Outside of the African region, [the United Kingdom](#), Germany, Sweden, Pakistan, India, and Thailand are the

only other nations with reported cases of clade 1b. The UK reported the first case of clade 1b mpox on October 30th, and announced three additional cases of clade 1b (household contacts of the initial case) on November 6th. The index case acquired mpox while traveling in Africa, and there has been no internal spread in the UK beyond the household contacts.

Regulatory

On September 13, the WHO granted [prequalification](#) to Bavarian Nordic's mpox vaccine (MVA-BN). This is **the first mpox vaccine to receive prequalification**. Two other mpox vaccines, ACAM2000 (Emergent BioSolutions) and LC16-KMB (KM Biologics)[GE1], are also under consideration. On October 8th, WHO [prequalification](#) for MVA-BN was **extended for use in adolescents** aged 12-17. Prequalification is often a prerequisite for organizations such as Gavi and UNICEF to begin procuring and distributing vaccines in LMICs. The Democratic Republic of Congo [granted](#) emergency use authorization in June for both MVA-BN and LC16-KMB vaccines. Nigeria has also [granted](#) emergency use authorization for the MVA-BN vaccine. On October 3rd, the [Alinity m mpox assay](#) was the **first in vitro diagnostic to receive emergency use listing** by the WHO. The [Alinity m mpox assay](#) is a PCR test that is able to provide a result in less than 2 hours. The Alinity m mpox assay is not considered a point of care or near of care PCR platform, but a lab-based diagnostic platform.

The WHO [has listed](#) two additional mpox diagnostics under emergency use listing (EUL). EUL has been granted to Cepheid's Xpert Mpox (Oct. 28) and Roche's cobas MPXV assay (Oct. 14), both of which are PCR-based diagnostic. Cobas MPXV can deliver results in less than 2 hours, and must be used on cobas systems. Xpert Mpox is compatible with GeneXpert systems, delivers results in under 40 minutes, and is the only near point-of-care diagnostic available for mpox at this time.

Vaccines


Supply:

The [estimated](#) need for vaccine doses is between **18-22 million doses** to meet the Africa CDC's goal of vaccinating at least 10 million people in 6 months. There are three existing vaccines that are effective against mpox: MVA-BN (Bavarian Nordic), ACAM2000 (Emergent BioSolutions), and LC16-KMB (KM Biologics), but at the present time the WHO recommends use of MVA-BN or LC16-KMB during an outbreak. Many doses of all three available vaccines are within high-income countries' national stockpiles, and **most countries have not disclosed the available quantity**. The U.S. [has over](#) 100 million doses of ACAM2000[GE2], and an unknown quantity of MVA-BN doses. It is unclear if the U.S. pledged doses for donation will come from the U.S. stockpile of vaccines. Canada [may have](#) up to 2 million doses of MVA-BN in the national stockpile. Japan [may have](#) up to 200 million doses of LC16-KMB, of which up to 3 million have been pledged. Spain [has pledged](#) 500,000 doses, which is around 20% of its stockpiles, while Germany [has pledged](#) 100,000 doses from its total military stockpile of 117,000 doses.

Manufacturing capacity:

Bavarian Nordic, the manufacturer of the MVA-BN mpox vaccine, [estimates](#) it can supply **13 million doses of the vaccine by the end of 2025**, and is exploring options to expand capacity. By the end of 2024, the company estimates 2 million doses could be supplied. Based on early discussions to [transfer manufacturing](#) to other companies there is the potential for **an additional 50 million doses to be supplied in the next 12-18 months**.

Confirmed mpox cases in 2024, Africa
from 01 Jan 2024, as of 15 Sep 2024



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the determination of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: WHO Health Emergencies Programme
© WHO 2024. All rights reserved.

Source: [WHO 2022-2024 Mpox Outbreak: Global Trends](#)

African vaccine manufacturers, Aspen Pharmacare and the Biovac Institute, have been in exploratory discussions with Bavarian Nordic about vaccine production. The potential for increasing manufacturing capacity is dependent on regulatory approvals and vaccine demand. With only 2 million doses that can be supplied by Bavarian Nordic by the end of 2024, **it will be critical for high-income countries with national stockpiles to donate doses** to meet the estimated need.

Procurement:


The European Health Emergency Response Authority [has negotiated](#) a joint contract to enable EU countries to access MVA-BN vaccines and tecovirimat for mpox. The exact cost of mpox vaccines is unclear, but it is estimated the [market price](#) of MVA-BN is around \$70-\$100 per dose, which would quickly deplete Gavi's \$500 million First Response Fund. Gavi has [announced](#) plans to purchase 500,000 doses of MVA-BN, using money from the First Response Fund to procure the doses and support the transportation, delivery, and costs of administering the vaccines. UNICEF has [announced](#) an **agreement to purchase 1 million doses of MVA-BN**, which includes the 500,000 doses that were committed by Gavi. Bavarian Nordic has stated all **1 million doses will be made available for supply by the end of 2024**.

Donations:

In the last two weeks, there have been no new donations of mpox vaccines announced. Fewer than 5.6 million vaccine doses have [been pledged](#) for donation. On September 24th, the United States [announced a donation of 1 million doses of the MVA-BN vaccine to the international mpox response](#). This marks the largest donation of MVA-BN mpox vaccines to date. This donation is in addition to the combined 60,000 doses the U.S. donated and delivered to Nigeria (10,000 doses) and the DRC (50,000 doses). The European Commission has pledged 566,500 doses. Canada has also [pledged](#) to donate up to 200,000 doses, stating that the number of doses delivered will be dependent on the receiving countries' capacity for storage and administration. The available mpox vaccines have less strict cold-chain requirements compared to COVID-19 vaccines and many available mpox vaccines can be stored in a refrigerator (see table below). Japan [has pledged](#) up to 3 million doses of the LC16-KMB vaccine. Nigeria [donated](#) 1,000 doses of mpox vaccines (from the 10,000 doses they received from the U.S.) to Rwanda.

The WHO and partners have [established](#) an **access and allocation mechanism (AAM) for mpox** medical countermeasures, including vaccines, treatments, and diagnostic tests. This mechanism was established as part of the interim Medical Countermeasures Network. The guiding principles for the mechanism are preventing illness and death, mitigating inequity, and ensuring transparency and flexibility. The AAM has [allocated](#) 899,000 mpox vaccines to 9 countries (Central African Republic, Cote d'Ivoire, the Democratic Republic of the Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa and Uganda). 85% of

these vaccines (765,200) will go to the Democratic Republic of the Congo which is currently the most affected country. These doses are expected to be delivered starting this week, and 975,700 doses will be the next batch of vaccines to be allocated and delivered in December.



Source: Publicly available data compiled by the COVID QuickStart team, last updated November 5, 2024

Delivery and uptake:

There have been no new deliveries of mpox vaccine doses in the last two weeks. A total of 280,880 vaccine doses have been delivered to 3 African countries. The majority of doses (265,460) were delivered to the DRC where it is estimated 3 million doses are required to end the mpox outbreaks. Nigeria has received 10,000 doses, and Rwanda has received 6,420 doses. Five countries have developed or are in the process of developing vaccination plans for mpox. **Both the Democratic Republic of Congo and Rwanda have begun vaccinating target populations**, while Nigeria is planning to roll-out vaccinations on November 18th. Rwanda began [administering](#) mpox vaccinations to high-risk populations starting on September 17th. The DRC began [administering](#) vaccinations on October 5th and [3 provinces \(Nord Kivu, Sud Kivu, and Tshopo\) have achieved or exceeded initial coverage targets with 142.8%, 121%, and 91.3% respectively.](#) The DRC has [exceeded](#) vaccination targets among front line health workers, rangers/hunters, and contacts of cases.

DRC vaccination coverage by target categories:

Target	Persons vaccinated	Target macro plan	Coverage
Front line workers	12,038	7,608	158%
Sex workers	5,129	13,896	37%
Transgender	226	2,283	10%
Men having sex with men	431	4,998	9%
Rangers/hunters	4,315	100	4315%
Contacts	22,352	17,072	131%

Source: [Africa CDC Special Press Briefing on Mpox Epi weeks 1-43](#)

Cold-chain requirements for available vaccines:

MVA-BN	Shipped frozen (-20°C); can be stored frozen for long-term storage or refrigerated (2°C-8°C) and stored for 8 weeks.
LC16-KMB	Can be stored for 2 years in a refrigerator or for 4 weeks at room temperature (37°C or below).
ACAM200 Q	After reconstitution, can be stored in a refrigerator for 30 days. The antigen component is shipped frozen and can be stored frozen until expiry or refrigerated for up to 18 months or expiry. The diluent can be stored from 15°C-30°C.

Testing and therapeutics

[Testing capacity](#) for mpox in the Democratic Republic of Congo remains low due to limited access to laboratory testing in remote areas. It is [estimated](#) only **around 40-50% of suspected cases have been tested**. The DRC is [decentralizing laboratory services in an effort to improve diagnostic speed](#). The only WHO approved diagnostics use PCR or near point-of-care PCR. Contipharma's LAMPOX and Monkeypox Virus Antigen Rapid Test Kit both recently received [market access authorization](#) in the Democratic Republic of Congo. These are among the first rapid diagnostic tests that could improve testing, but further evaluation is needed to better understand performance and clade differentiation. It is important to note that at this time, the **Africa CDC has emphasized no antigen rapid diagnostic test has demonstrated the minimum requirement for mpox testing**. The WHO is in the process of reviewing additional requests for diagnostic manufacturing approvals for mpox. In response to rising cases of mpox in Uganda, the U.S. has [donated](#) 5,000 laboratory test kits (bringing the total donated to 10,000) to support testing efforts in the country. The Africa CDC and WHO have [distributed](#) 7,000 GeneXpert machines and cartridges to Burundi, Cameroon, the Central African Republic, Congo, Côte d'Ivoire, the Democratic Republic of Congo, Kenya, Liberia, Rwanda and Zambia alongside 11,000 tests. Additionally, the Africa CDC has [provided](#) 7 sets of sequencing equipment to Burundi, Ethiopia, Kenya, Mauritania, Sierra Leone, and Zimbabwe.

There remains no therapeutic that has received WHO approval for mpox. Tecovirimat only has approval in the EU and US under animal rule and exceptional circumstances for mpox. [Proper use](#) of tecovirimat requires taking the medication within 30 minutes of eating a moderate or high fat meal for the full 14 day course of treatment. This may present difficulties for use in areas experiencing acute food insecurity such as the [Democratic Republic of Congo](#). Results of the [PALM007 trial](#) for tecovirimat in the Democratic Republic of Congo showed the antiviral drug was safe **but did not reduce the duration of mpox lesions in patients** with clade 1 mpox. The study largely included participants under the age of 18 and limited representation of persons living with HIV. Ongoing clinical trials aim to further understand why tecovirimat did not confer benefit, new approaches to treating mpox, and evaluating tecovirimat further in adults and people living with HIV infected with clade 2 mpox. Some monoclonal antibodies (mAbs) are in preclinical development, though it will be critical to consider the potential downstream accessibility of these candidates. SIGA has [entered](#) into an exclusive license agreement with Vanderbilt University for novel poxvirus monoclonal antibodies, though it will be critical to consider the potential downstream accessibility of this candidate.

Therapeutics | 100 Days Mission mpox tracker

Day 60 of mpox PHEIC
 13th October 2024

Candidate Manufacturer	WHO-listed authority approved for mpox	WHO EUL	Use in under- 18s	Ongoing trials ^①	Availability	Manufacturing capability	Comments
Tecovirimat* Siga	✔ EMA†	✘	✘	6 ○ Ph I ● Ph II ● Ph III ○ Ph IV	South Africa; used under EA-IND for mpox in USA	Easily manufactured at scale	Primary endpoint not met in PALM007 (Clade I in DRC) PK/PD and resistance results awaited
Brincidofovir Emergent BioSolutions	✘	✘	✘	0 ○ Ph I ○ Ph II ○ Ph III ○ Ph IV	Used under EIND for mpox in the USA	N/A	To be tested in the MOSA trial in DRC, Nigeria
VIGIV Emergent BioSolutions	✘	✘	✘	1 ● Ph I ○ Ph II ○ Ph III ○ Ph IV	N/A	N/A	Manufacturing/access at scale not currently feasible in LMICs
Cidofovir Gilead	✘	✘	✘	0 ○ Ph I ○ Ph II ○ Ph III ○ Ph IV	N/A	N/A	N/A

Novel antivirals: 3 novel antiviral candidates for mpox in preclinical development; **1 in early clinical development (ASC10)**
Monoclonal antibodies (mAbs): 2 anti-mpox mAbs with ongoing preclinical studies [BFI 753 (Biofactura) and JEPO-CBRND (Just Evotec)]

KEY: Repurposed

* Available for compassionate use in South Africa and for clinical trials in the DRC and CAR or under application to MEURL, but no African country has applied for or completed an application to MEURI at this time.

† Approved under animal rule/ exceptional circumstances

EIND: emergency investigational new drug
 PK/PD: pharmacokinetics / pharmacodynamics
 EA-IND: expanded access-investigational new drug
 ① Source: Pandemic PACT Programme

Source: [International Pandemic Preparedness Secretariat and Pandemic PACT Programme](#)

Financing

The [Mpx Continental Preparedness and Response Plan for Africa](#) requested an **estimated budget of nearly \$600 million USD**, of which around \$329 million (55%) will be allocated for mpox response across 14 countries and mpox readiness in 15 additional countries. The other nearly \$270 million (45%) has been earmarked for operational and technical support through partners. The budget included in the Africa CDC and WHO Mpox Continental Preparedness and Response Plan for Africa does not include costs associated vaccine procurement, which is dependent on price negotiations with manufacturers and donated doses. **Africa CDC has reported they received pledges totaling \$1.3 billion USD from both international and domestic sources.** Publicly available pledges have been reported below.

New financial pledges:

Democratic Republic of Congo	\$10 million to support response efforts
African Union	\$10.4 million to support response efforts
European Union	€20 million towards implementation of the joint Africa CDC/WHO Mpox Continental Preparedness and Response Plan
United States	at least \$500 million to support response efforts to be delivered bilaterally and through multilateral institutions
Gavi	\$2.9 million from existing funds to support the DRC's vaccination efforts
Global Fund	\$9.5 million to support the DRC's response
United Kingdom	£9 million for mpox response in central Africa, including deployment of technical experts
CEPI	\$217 million
Pandemic Fund	\$128.89 million fast-tracked to support 10 countries in mpox response
Burundi, Gabon, Côte d'Ivoire, Rwanda	\$1 million from each country has been pledged to the response

Total estimated pledges for mpox response: USD \$554,400,000

[The Pandemic Fund](#) has decided, under the Fund's second call for proposals, **to fast-track US \$128.89 million to support 10 countries** in their response to mpox. This funding will go to projects that aim to enhance national and cross-border surveillance and early warning systems; strengthen laboratory capacities for disease detection, sequencing, and genomic surveillance; build a skilled workforce equipped to detect and rapidly respond to health threats and emergencies; and foster multisectoral coordination for pandemic prevention, preparedness, and response through a One Health approach. The 10 countries are: the DRC, Burundi, Rwanda, Uganda, Kenya, Sudan, Djibouti, Ethiopia, Somalia, and South Sudan.

In the news

Africa CDC mpox dashboard: <https://dashboards.africacdc.org/>

Africa CDC statement on Antigen Rapid Tests for mpox: <https://africacdc.org/download/statement-on-antigen-rapid-tests-for-mpox-diagnosis-30-october-2024/>

Pandemic Fund raises US\$982 million in new commitments from governments: <https://www.thepandemicfund.org/news/press-release/pandemic-fund-raises-us982-million-new-commitments-governments-and-additional>

Mpox vaccine generates robust response in adolescents: <https://www.nih.gov/news-events/news-releases/mpox-vaccine-safe-generates-robust-antibody-response-adolescents>

WHO approves additional mpox diagnostic test: <https://www.who.int/news/item/30-10-2024-who-lists-additional-mpox-diagnostic-tests-for-emergency-use>

INTREPID Alliance releases antiviral landscape analysis: <https://www.intrepidalliance.org/antiviral-pipeline/>

Pandemic PACT mpox outbreak page: <https://www.pandemicpact.org/outbreaks/mpox>

Acknowledgements:

The primary author is Katharine Olson with review support from Elina Urli Hodges, Krishna Udayakumar, Gary Edson, Mike Merson, Sean Regan, Jessica Joseph, and Caroline Boeke. The authors are grateful to the entire QuickStart team for their input, and particularly thank Melissa Estrada for her design support and Harper Cheng for her support in data collection and management. The content and recommendations in this report is an independent effort by QuickStart, without approval by any external parties. It does not necessarily reflect the viewpoints of funders or any person who contributed to discussions with the QuickStart team that helped inform this report.

Contact us

 <http://covidquickstart.org/>

 quickstart@duke.edu